Table 1. Patient Characteristics . ALL .... | American Society of Hematology

Table 1.

Patient Characteristics

	ALL	IDM/HDM^-150	MP^-151
No. patients	70	32	38
Age
Median	61	52	67
Range	34-86	35-65	35-85
Sex (male:female)	44:26	18:14	26:12
M-component
IgG	44	22	22
IgA	16	7	9
IgD	1		1
LCD	9	3	6
k:λ	41:29	19:13	22:16
Stage:
II-A	13	5	8
III-A	50	25	25
III-B	7	2	5
Performance status (ECOG)
0	9	4	5
1	22	9	13
2	21	9	12
3	13	7	6
4	5	3	2

	ALL	IDM/HDM^-150	MP^-151
No. patients	70	32	38
Age
Median	61	52	67
Range	34-86	35-65	35-85
Sex (male:female)	44:26	18:14	26:12
M-component
IgG	44	22	22
IgA	16	7	9
IgD	1		1
LCD	9	3	6
k:λ	41:29	19:13	22:16
Stage:
II-A	13	5	8
III-A	50	25	25
III-B	7	2	5
Performance status (ECOG)
0	9	4	5
1	22	9	13
2	21	9	12
3	13	7	6
4	5	3	2

Abbreviation: LCD, light chain disease.

F0-150

Patients treated with 2 courses of intravenous intermediate dose melphalan, 70 mg/m² with an interval of 6 weeks (n = 20) or a single IV high-dose melphalan, 140 mg/m² (n = 12).

F0-151

Patients treated with intermittent oral melphalan 0.25 mg/kg/d and prednisone 2 mg/kg/d.

View Large

This Feature Is Available To Subscribers Only